Scarica l'app Stockscreener
6.88
12.58%
-0.99
Dopo l'orario di chiusura:
6.79
-0.09
-1.31%
Precedente Chiudi:
$7.87
Aprire:
$7.9
Volume 24 ore:
223.71K
Relative Volume:
1.33
Capitalizzazione di mercato:
$178.90M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-0.1382
EPS:
-49.8
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
-17.60%
1M Prestazione:
+9.55%
6M Prestazione:
-35.34%
1 anno Prestazione:
-61.61%
Intervallo 1D:
$6.86
$7.90
Intervallo di 1 settimana:
$6.86
$8.3999
Portata 52W:
$5.98
$18.80
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.88 | 204.65M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Cartesian Therapeutics (RNAC) to Release Earnings on Thursday - MarketBeat
Published on: 2026-03-02 22:13:30 - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cartesian Therapeutics to present at TD Cowen Health Care Conference in Boston - Traders Union
RNAC Should I Buy - Intellectia AI
Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews
Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock? - MSN
Published on: 2026-02-25 09:47:28 - baoquankhu1.vn
Aug Sentiment: What is the earnings history of Cartesian Therapeutics IncWeekly Market Outlook & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Bitget
What drives Cartesian Therapeutics Inc.’s stock priceQuarterly Trade Review & Real-Time Buy Zone Alerts - mfd.ru
Institution Moves: What’s the MACD signal for Cartesian Therapeutics Inc.2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: Unpacking a 435.71% Potential Upside in Biotech - DirectorsTalk Interviews
Analyst Upgrade: Is Cartesian Therapeutics Inc attractive for institutional investorsEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Trading Recap: What are Zenas BioPharma Incs growth leversMarket Trend Review & Verified Entry Point Detection - baoquankhu1.vn
Is Cartesian Therapeutics Inc. stock positioned well for digital economyTrade Volume Summary & Community Verified Trade Signals - mfd.ru
Is Cartesian Therapeutics Inc.’s ROE strong enoughWeekly Gains Report & Risk Managed Investment Entry Signals - mfd.ru
FMR LLC Reduces Stake in Cartesian Therapeutics Inc: A Strategic Portfolio Adjustment - GuruFocus
Is Cartesian Therapeutics Inc. a defensive stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Can JCTC stock outperform in a bear market2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 420% Potential Upside in Biotechnology - DirectorsTalk Interviews
Cartesian Therapeutics (RNAC) Issues New Stock Options to Employ - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - marketscreener.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 0.6%Here's What Happened - MarketBeat
Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely? - Sahm
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Can a 388.62% Upside Fuel Your Investment Strategy? - DirectorsTalk Interviews
Smart Money: Is Cartesian Therapeutics Inc trading at a discountJuly 2025 Trends & Weekly High Return Stock Forecasts - baoquankhu1.vn
Stop Loss: Will Cartesian Therapeutics Inc outperform during market ralliesJuly 2025 Momentum & Real-Time Volume Spike Alerts - baoquankhu1.vn
Aug Mood: Is Cartesian Therapeutics Inc stock a top performer YTDJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Pharma News: Does Cartesian Therapeutics Inc have declining or rising EPSQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-01-22 19:08:46 - mfd.ru
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Risk Check: Is Cartesian Therapeutics Inc benefiting from interest rate changes2025 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
Why Cartesian Therapeutics Inc. stock is a value investor pickMarket Growth Summary & Reliable Price Action Trade Plans - ulpravda.ru
Cartesian Therapeutics (RNAC): Needham Raises Price Target to $4 - GuruFocus
Myasthenia Gravis Market Positioned for Accelerated - openPR.com
Cartesian Therapeutics highlights recent progress and outlines 2026 outlook - marketscreener.com
Cartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile Dermatomyositis - Quiver Quantitative
Cartesian Therapeutics Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewswire
What momentum indicators show for Cartesian Therapeutics Inc. stockQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда
Is Cartesian Therapeutics Inc. stock resilient to inflationJuly 2025 Final Week & Growth Focused Stock Pick Reports - Улправда
Cartesian Therapeutics (NASDAQ:RNAC) CFO Sells $72,230.62 in Stock - MarketBeat
Is Cartesian Therapeutics Inc. stock supported by innovation pipelineWeekly Stock Report & Free Technical Pattern Based Buy Signals - ulpravda.ru
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 354.71% Potential Upside in the Biotech Frontier - DirectorsTalk Interviews
Is Cartesian Therapeutics Inc. stock a buy before product launches2026 world cup usa national team quarterfinals defensive leaders transition play group prediction preview - Улправда
Cartesian Therapeutics, Inc.Common Stock (NQ: RNAC - FinancialContent
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):